Premium
‘Last‐ditch’ use of recombinant factor VIIa in patients with massive haemorrhage is ineffective
Author(s) -
Clark A. D.,
Gordon W. C.,
Walker I. D.,
Tait R. C.
Publication year - 2004
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.0042-9007.2004.00393.x
Subject(s) - medicine , coagulopathy , recombinant factor viia , factor viia , retrospective cohort study , surgery , blood transfusion , anesthesia , coagulation , tissue factor
Background and Objectives The aim of this retrospective study was to assess the effect of activated recombinant factor VII (rFVIIa) on the natural history of massive transfusion episodes. Materials and Methods During 2002, outcome parameters were assessed in 50 patients transfused with more than 10 units of packed red cells. The effect of the addition of rFVIIa in 10 patients, with intractable bleeding, was then observed. Results Overall mortality was 20% at 24 h and 34% at 7 days. Severe coagulopathy was confirmed as a serious negative prognostic factor and occurred in 42% of patients overall, but in 70% of rFVIIa‐treated patients. Transient cessation or reduction of bleeding was noted in 60% of patients following rFVIIa infusion. However, 24‐h and 7‐day mortality rates were 40% and 70%, respectively, in this group. Conclusions Last‐ditch rFVIIa therapy in patients resistant to conventional treatment did not rescue these patients or significantly alter outcomes.